Evident LogoOlympus Logo

Cell Counter model R1

Protocol Parameters

Name: Description

FF hiPS:Feeder-free Human iPS cells (201B7 cell line)

FF hiPS:Feeder-free Human iPS cells (201B7 cell line)
Protocol Results
Noise reduction: 6
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.50 x 106
Live cell conc. (cells/ml): 1.38 x 106
Dead cell conc. (cells/ml): 1.19 x 105
Viability (%): 92.0
Average cell size (μm): 15.9

MEF:Murine embryonic Fibroblasts

MEF:Murine embryonic Fibroblasts
Protocol Results
Noise reduction: 7
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: None
Total cell conc. (cells/ml): 1.03 x 106
Live cell conc. (cells/ml): 9.37 x 105
Dead cell conc. (cells/ml): 9.72 x 104
Viability (%): 90.6
Average cell size (μm): 19.6

A549: Human lung carcinoma

A549: Human lung carcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.09 x 106
Live cell conc. (cells/ml): 1.07 x 106
Dead cell conc. (cells/ml): 1.78 x 104
Viability (%): 98.4
Average cell size (μm): 17.5

AsPC-1: Human pancreatic adenocarcinoma

AsPC-1: Human pancreatic adenocarcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: High
Total cell conc. (cells/ml): 7.51 x 105
Live cell conc. (cells/ml): 7.19 x 105
Dead cell conc. (cells/ml): 3.17 x 104
Viability (%): 95.8
Average cell size (μm): 10.7

C6: Rat glioma

C6: Rat glioma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.31 x 106
Live cell conc. (cells/ml): 1.22 x 106
Dead cell conc. (cells/ml): 8.91 x 104
Viability (%): 93.2
Average cell size (μm): 12.1

Capan-2: Human pancreatic adenocarcinoma

Capan-2: Human pancreatic adenocarcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.04 x 106
Live cell conc. (cells/ml): 1.00 x 106
Dead cell conc. (cells/ml): 3.61 x 104
Viability (%): 96.5
Average cell size (μm): 13.4

DU 145: Human prostate carcinoma

DU 145: Human prostate carcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.86 x 106
Live cell conc. (cells/ml): 1.80 x 106
Dead cell conc. (cells/ml): 5.34 x 104
Viability (%): 97.1
Average cell size (μm): 14.3

293-GFP: HEK293 stably expressing GFP

293-GFP: HEK293 stably expressing GFP
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.84 x 106
Live cell conc. (cells/ml): 1.82 x 106
Dead cell conc. (cells/ml): 2.23 x 104
Viability (%): 98.8
Average cell size (μm): 11.3

H1299: Human non-small cell lung carcinoma

H1299: Human non-small cell lung carcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 4.14 x 105
Live cell conc. (cells/ml): 3.52 x 105
Dead cell conc. (cells/ml): 6.23 x 104
Viability (%): 84.9
Average cell size (μm): 19.5

H4: Human neuroglioma

H4: Human neuroglioma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 2.08 x 105
Live cell conc. (cells/ml): 1.44 x 105
Dead cell conc. (cells/ml): 6.32 x 104
Viability (%): 69.6%
Average cell size (μm): 12.8

HCT116: Human colorectal carcinoma

HCT116: Human colorectal carcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.34 x 106
Live cell conc. (cells/ml): 1.32 x 106
Dead cell conc. (cells/ml): 1.81 x 104
Viability (%): 98.7
Average cell size (μm): 12.2

HeLa: Human cervical carcinoma*

Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 8.98 x 105
Live cell conc. (cells/ml): 8.11 x 105
Dead cell conc. (cells/ml): 8.69 x 104
Viability (%): 90.3
Average cell size (μm): 17.6

Hep3B: Human hepatocellular carcinoma

Hep3B: Human hepatocellular carcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.54 x 106
Live cell conc. (cells/ml): 1.49 x 106
Dead cell conc. (cells/ml): 5.87 x 104
Viability (%): 96.2
Average cell size (μm): 14.9

HL-60: Human acute promyelocytic leukemia

HL-60: Human acute promyelocytic leukemia
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.57 x 106
Live cell conc. (cells/ml): 1.45 x 106
Dead cell conc. (cells/ml): 1.23 x 105
Viability (%): 92.2
Average cell size (μm): 14.9

Hs 578T: Human mammary carcinoma

Hs 578T: Human mammary carcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.13 x 106
Live cell conc. (cells/ml): 8.72 x 105
Dead cell conc. (cells/ml): 2.62 x 105
Viability (%): 76.9
Average cell size (μm): 16.5

MCF7: Human breast adenocarcinoma

MCF7: Human breast adenocarcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 4.74 x 105
Live cell conc. (cells/ml): 4.43 x 105
Dead cell conc. (cells/ml): 4.07 x 104
Viability (%): 91.4
Average cell size (μm): 16.2

NIH3T3: Mouse embryonic fibroblast

NIH3T3: Mouse embryonic fibroblast
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.52 x 106
Live cell conc. (cells/ml): 1.33 x 106
Dead cell conc. (cells/ml): 1.96 x 105
Viability (%): 87.1
Average cell size (μm): 14.1

PANC-1: Human pancreatic ductal carcinoma

PANC-1: Human pancreatic ductal carcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: High
Total cell conc. (cells/ml): 1.23 x 106
Live cell conc. (cells/ml): 1.21 x 105
Dead cell conc. (cells/ml): 2.26 x 104
Viability (%): 98.2
Average cell size (μm): 15.3

PC-3: Human prostate adenocarcinoma

PC-3: Human prostate adenocarcinoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.36 x 106
Live cell conc. (cells/ml): 1.33 x 106
Dead cell conc. (cells/ml): 3.16 x 104
Viability (%): 97.7
Average cell size (μm): 17.2

STO: Mouse embryonic fibroblast

STO: Mouse embryonic fibroblast
Protocol Results
Noise reduction: 5
Roundness: 0%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.78 x 106
Live cell conc. (cells/ml): 1.50 x 106
Dead cell conc. (cells/ml): 2.81 x 105
Viability (%): 84.2
Average cell size (μm): 13.1

U-2 OS: Human osteosarcoma

U-2 OS: Human osteosarcoma
Protocol Results
Noise reduction: 5
Roundness: 60%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 7.66 x 105
Live cell conc. (cells/ml): 7.21 x 105
Dead cell conc. (cells/ml): 4.45 x 104
Viability (%): 94.2
Average cell size (μm): 16.0

U937: Human lymphoma

U937: Human lymphoma
Protocol Results
Noise reduction: 5
Roundness: 40%
Min. cell size (μm): 3
Max. cell size (μm): 60
Declustering level: Medium
Total cell conc. (cells/ml): 1.22 x 106
Live cell conc. (cells/ml): 1.12 x 106
Dead cell conc. (cells/ml): 1.02 x 105
Viability (%): 91.6
Average cell size (μm): 13.4


*Although it became one of the most important cell lines in medical research, it’s imperative that we recognize Henrietta Lacks’ contribution to science happened without her consent. This injustice, while leading to key discoveries in immunology, infectious disease, and cancer, also raised important conversations about privacy, ethics, and consent in medicine.
To learn more about the life of Henrietta Lacks and her contribution to modern medicine, click here.
http://henriettalacksfoundation.org/

Sorry, this page is not
available in your country.

Get in Touch

Sorry, this page is not available in your country